Table 1.
Comparison of baseline characteristics and clinical data between patients with different initial empirical antibiotic treatments
| Non-IIAT (n=71) | IIAT (n=176) | P-value | |
|---|---|---|---|
| Age, years (mean ± SD) | 38.6±14.7 | 38.8±15.8 | 0.963 |
| Sex (M/F) | 51/20 | 99/77 | 0.023 |
| Duration of fever (days), median (range) | 3 (0–35) | 4 (0–54) | 0.179 |
| Underlying disease | 0.831 | ||
| Acute lymphoblastic leukemia, n (%) | 25 (35.2%) | 61 (34.7%) | |
| Acute myeloid leukemia, n (%) | 31 (43.7%) | 83 (47.1%) | |
| Other hematologic malignancya, n (%) | 15 (21.1%) | 32 (18.2%) | |
| Treatment typeb | 0.592 | ||
| Hematopoietic stem–cell transplantation, n (%) | 27 (38.0%) | 71 (40.3%) | |
| High-dose chemotherapy, n (%) | 33 (46.5%) | 86 (48.9%) | |
| Other chemotherapy, n (%) | 11 (15.5%) | 19 (10.8%) | |
| Complications (grade 2–4) | |||
| Ventilator support, n (%) | 6 (8.5%) | 13 (7.4%) | 0.795 |
| Liver damage, n (%) | 23 (32.4%) | 78 (44.6%) | 0.079 |
| Respiratory failure, n (%) | 8 (11.3%) | 33 (18.9%) | 0.148 |
| Renal insufficiency, n (%) | 47 (66.2%) | 105 (60%) | 0.365 |
| Bleeding, n (%) | 26 (36.6%) | 67 (38.3%) | 0.807 |
| Diabetes, n (%) | 3 (4.2%) | 5 (2.9%) | 0.693 |
| Heart failure, n (%) | 4 (5.6%) | 18 (10.3%) | 0.247 |
| Death, n (%) | 17 (23.9%) | 66 (37.7%) | 0.038 |
Notes: aOther hematologic diseases included multiple myeloma, myelodysplastic syndromes, non-Hodgkin’s lymphoma, and Hodgkin's lymphoma; btreatment regimens and classification summarized in Supplementary Table 1.